A highly concentrated solution can be difficult to measure accurately, and a small error in measurement can lead to a massive error in your experimental results
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Managing injection site reactions Redness, swelling, or itching at the injection site affects a subset of patients
Nonogaki, K., Nozue, K
Days 7-14: Initial improvements in pain levels, reduced swelling, and early signs of healing become more consistently reported
We recommend using the smallest appropriate gauge, typically 23-25g